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Histone deacetylase (HDAC) inhibitors induce cell cycle
arrest, differentiation or apoptosis in tumour cells and
are, therefore, promising anti-cancer reagents. However,
the speciﬁc HDAC isoforms that mediate these effects
are not yet identiﬁed. To explore the role of HDAC1 in
tumourigenesis and tumour proliferation, we established
an experimental teratoma model using wild-type and
HDAC1-deﬁcient embryonic stem cells. HDAC1-deﬁcient
teratomas showed no signiﬁcant difference in size com-
pared with wild-type teratomas. Surprisingly, loss of
HDAC1 was not only linked to increased apoptosis, but
also to signiﬁcantly enhanced proliferation. Epithelial
structures showed reduced differentiation as monitored
by Oct3/4 expression and changed E-cadherin localization
and displayed up-regulated expression of SNAIL1, a reg-
ulator of epithelial cell plasticity. Increased levels of the
transcriptional regulator SNAIL1 are crucial for enhanced
proliferation and reduced differentiation of HDAC1-deﬁ-
cient teratoma. Importantly, the analysis of human terato-
mas revealed a similar link between loss of HDAC1 and
enhanced tumour malignancy. These ﬁndings reveal a
novel role for HDAC1 in the control of tumour proliferation
and identify HDAC1 as potential marker for benign
teratomas.
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Introduction
The architecture of eukaryotic chromatin is of critical impor-
tance for the regulation of gene expression. Local changes in
chromatin structure affect transcriptional activity and are
dynamically modulated by post-translational modiﬁcations
of core histone proteins (reviewed in Jenuwein and Allis,
2001). Reversible acetylation of N-terminal tails is one of the
best-studied post-translational protein modiﬁcations. Histone
acetylation—mediated by histone acetyltransferases—is gen-
erally associated with transcriptional activation, whereas
histone deacetylation—catalysed by histone deacetylases
(HDACs)—typically leads to transcriptional repression
(reviewed in Wade, 2001). Eighteen mammalian HDACs
have been identiﬁed to date and are classiﬁed according to
their homology to yeast deacetylases (reviewed in
Mariadason, 2008): Rpd3-like class I (HDAC1, 2, 3, and 8),
Hda1-like class IIa (HDAC4, 5, 7, and 9) and class IIb (HDAC6
and 10), Sir2-like class III (SIRT1-7), and class IV (HDAC11).
In addition to histones, HDACs also deacetylate non-histone
proteins, including transcription factors, tumour suppressors,
signal transduction mediators, and cytoskeleton components
(reviewed in Lin et al, 2006; Glozak and Seto, 2007; Spange
et al, 2009).
HDACs have crucial roles in the regulation of a variety
of biological processes, including cell cycle progression,
proliferation, differentiation, and development (reviewed
in Haberland et al, 2009b). In recent years, it has also
become increasingly evident that HDACs are involved in
the pathogenesis of cancer (reviewed in Weichert, 2009).
Consequently, HDAC inhibitors have attracted considerable
attention as potential anti-cancer drugs. HDAC inhibitors
selectively induce growth arrest, differentiation, and/or apop-
tosis in transformed cell lines and tumour-bearing animals
(reviewed in Bolden et al, 2006; Marks and Xu, 2009). Several
HDAC inhibitors are currently tested in Phase I/II clinical
trials for their efﬁcacy as anti-cancer agents, and the HDAC
inhibitor suberoylanilide hydroxamic acid was recently FDA
approved for the treatment of cutaneous T-cell lymphoma
(Mann et al, 2007 and reviewed in Marks and Xu, 2009).
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3992Most HDAC inhibitors described so far inhibit multiple class I,
II, and IV HDAC isoforms, and the key HDACs targeted by
these drugs in cancer therapy have yet to be identiﬁed
(reviewed in Balasubramanian et al, 2009; Witt et al, 2009).
Insight into the relevance of speciﬁc HDACs in tumourigenesis
have, however, been obtained from loss-of-function studies in
cells and animal models, and from the analysis of HDAC
expression in various types of human cancers (Ozdag et al,
2006; Nakagawa et al, 2007; Zimmermann et al, 2007; Jin
et al, 2008; Haberland et al, 2009b; Weichert, 2009).
The class I enzyme HDAC1 is essential for the development
of mouse embryos (Lagger et al, 2002; Montgomery et al,
2007; Yamaguchi et al, 2010) and unrestricted proliferation
of embryonic stem (ES) cells (Lagger et al, 2002), and is
involved in epithelial cell differentiation (reviewed
in Brunmeir et al, 2009). The highly homologous class I
enzymes HDAC1 and HDAC2 are able to homo- and hetero-
dimerise and are frequently recruited to the same repressor
complexes indicating similar or partly overlapping functions
(Hassig et al, 1998; Taplick et al, 2001). However, a conven-
tional mouse knockout study identiﬁed that loss of HDAC1
results in a pleiotropic phenotype accompanied by reduced
proliferation rates and embryonic lethality before embryonic
day E9.5 (Lagger et al, 2002). Interestingly, HDAC2 is
up-regulated in HDAC1-deﬁcient embryos and ES cells, but
can obviously not compensate for the loss of HDAC1 (Lagger
et al, 2002; Zupkovitz et al, 2006). In contrast, three knockout
mouse studies for HDAC2 report no embryonic lethality
(Trivedi et al, 2007; Zimmermann et al, 2007; Yamaguchi
et al, 2010), underlining the critical role of HDAC1 during
embryonic development and suggesting non-redundant func-
tions for both enzymes in several cases. Deletion of either
HDAC1 or HDAC2 in a wide range of tissues does not affect
viability, but loss of all four Hdac1/Hdac2 alleles leads to
severe tissue-speciﬁc phenotypes (Montgomery et al, 2007,
2009). However, the exact molecular mechanism of HDAC1
and HDAC2 cross-regulation remains a matter of debate.
Cumulative observations also indicate that HDAC1 is im-
plicated in the pathogenesis of cancer, and is a crucial target
for HDAC inhibitors in cancer therapy. Increased HDAC1
expression has been reported in a variety of human cancers,
including breast (Krusche et al, 2005), colon and colorectal
(Giannini and Cavallini, 2005; Huang et al, 2005; Wilson
et al, 2006; Ishihama et al, 2007; Weichert et al, 2008c;
Thangaraju et al, 2009), endometrial (Weichert et al,
2008a), gastric (Choi et al, 2001; Kim et al, 2004), hepatocel-
lular (Rikimaru et al, 2007), pancreatic (Wang et al, 2009),
prostate (Patra et al, 2001; Halkidou et al, 2004; Weichert
et al, 2008b), and ovarian (Jin et al, 2008; Weichert et al,
2008a) cancers. A number of knockdown studies using small-
interfering RNA have shown that loss of HDAC1 leads to
reduced proliferation, cell cycle arrest, and induction of
apoptosis in a variety of human tumour cell lines (Glaser
et al, 2003; Senese et al, 2007; Thangaraju et al, 2009),
indicating that HDAC1 is essential for tumour cell survival.
Cellular differentiation was reported in human breast cancer
cell lines following down-regulation of HDAC1 (Zhou et al,
2000), accordingly HDAC1 expression correlates with poor
tumour differentiation in various human cancers (Rikimaru
et al, 2007; Wang et al, 2009; Weichert, 2009). A potential
involvement of HDAC1 in lymphoma and leukaemia forma-
tion (Minucci et al, 2000; Amann et al, 2001), breast cancer
progression (Kawai et al, 2003; Suzuki et al, 2009), tumour
angiogenesis (Kim et al, 2001), tumour invasion and metas-
tasis (Peinado et al, 2004; von Burstin et al, 2009), and
tumour resistance to oxidative stress (Kato et al, 2009) has
been reported.
To evaluate the role of HDAC1 in tumour formation, we
experimentally induced teratomas (i.e. germ cell tumours) in
immunodeﬁcient mice. We report for the ﬁrst time that
HDAC1 deﬁciency leads to formation of partially undifferen-
tiated embryonal carcinomas in a murine teratoma model
system. This phenotype is accompanied by up-regulation of
HDAC2, the closest homologue of HDAC1. In contrast,
tumours derived from wild-type ES cells are highly differen-
tiated and show less proliferation. These results can be
explained by loss of HDAC1-mediated repression of the
Snail1 gene in HDAC1 /  tumours. As a consequence of
elevated SNAIL1 expression, E-cadherin is delocalised, lead-
ing to loss of cell junctions and reduced epithelial structures.
Remarkably, the murine phenotype was mirrored in human
patient samples. Similar to the mouse teratoma model,
HDAC1 was highly expressed in mature (differentiated)
human patient samples, whereas HDAC2 was found over-
expressed in immature (undifferentiated) samples. These
results suggest that HDAC1 and HDAC2 could represent
valuable prognostic markers for carcinoma classiﬁcation in
the future.
Results
HDAC1þ/þ and HDAC1 /  ES cells form teratomas
Various recent publications suggest functions for HDACs in
cancer formation and progression (Ozdag et al, 2006;
Nakagawa et al, 2007). However, the exact mechanism of
action or which members of the class I HDAC family partici-
pate in the emergence of cancer, have not been clariﬁed so
far. The conventional knockout of HDAC1 in mice revealed
reduced proliferation rates in mouse embryos and ES cells
identifying HDAC1 as an important regulator of cellular
proliferation (Lagger et al, 2002). To evaluate the contribution
of HDAC1 to cancer formation, we made use of a common
tumour and differentiation system that is the generation of
teratomas in immunodeﬁcient mice. Therefore, either HDAC1
wild-type (HDAC1þ/þ) or knockout (HDAC1 / ) ES cells
were subcutaneously injected in SCID/BALBc female mice
and monitored every 4 days (for a list of all injections see
Supplementary Table S1). As controls, we used HDAC1
reintroduced (HDAC1 / re) and empty vector infected
(HDAC1 / ev) knockout ES cells as previously described
(Zupkovitz et al, 2006). Palpable tumour masses developed
usually at the sites of injection within 4 to 16 days in the case
of HDAC1þ/þ and HDAC1 /  ES cells and 4 to 12 days for
HDAC1 / re and HDAC1 / ev ES cells (Supplementary
Figure S1A). Interestingly, all ES cell lines injected led to
the development of tumours, indicating that onset and pri-
mary teratoma formation is independent of the presence of
HDAC1. When tumours reached an estimated volume
of 1000–1500mm
3, mice were killed and teratomas of all
genotypes were removed, measured, and weighed. Although
a tendency for teratomas derived from HDAC1 mutant ES
cells to develop more slowly and to be smaller than teratomas
derived from wild-type ES cells was noticed, no statistically
signiﬁcant difference (Student’s t-test: P-value 40.05) was
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teratomas derived from HDAC1 wild-type and HDAC1 mutant
ES cells (Figure 1A). The tumour volume of teratomas
resulting from the injection of HDAC1 / ev ES cells was
even slightly increased when compared with the size of
HDAC1 / re teratomas (Supplementary Figure S1A). In
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development or adjacent tissue invasion was detected during
the course of the experiment. Teratomas remained localised
to the site of ES cell injection and appeared not to affect the
health of host mice (data not shown).
In the next experiment, we examined the expression
levels of HDAC1 and its closest homologue HDAC2 in terato-
mas by western blot analyses (Figure 1B; Supplementary
Figure S1B). We had previously observed an up-regulation
of HDAC2 in HDAC1 mutant ES cells (Lagger et al, 2002).
As expected, HDAC1 was absent in teratomas generated from
HDAC1 /  and HDAC1 / ev ES cells, whereas HDAC2 was
found to be up-regulated. In order to survey the tissue
composition of teratomas from different genotypes, tumours
were parafﬁn embedded and sectioned. Further conﬁrmation
that HDAC1 is undetectable in HDAC1 mutant teratomas was
achieved by immunohistochemical (IHC) experiments, re-
vealing that HDAC1 expression was reduced by B80%
when compared with wild-type teratomas (Figure 1C).
In HDAC1 /  teratomas, a small minority of cells (2%)
retained HDAC1 expression. These HDAC1-positive cells
were identiﬁed to form blood vessels or to be immigrated
immune cells. We, therefore, suggest that these cells origin-
ally descend from the host mouse and did not arise from
the injected ES cell lines. In accordance with the western
blot analyses, we found HDAC2 overexpressed upon loss of
HDAC1 in IHC stainings (Figure 1C). The number of HDAC2-
positive cells in HDAC1 /  teratomas increased from 35 to
83% when compared with wild-type tumours.
These results show that injection of HDAC1 wild-type and
mutant ES cells in immunodeﬁcient mice led to the formation
of teratomas, but unexpectedly revealed no statistical differ-
ence in tumour volume and growth behaviour.
HDAC1 /  teratomas exhibit elevated proliferation
and apoptosis
An important feature of cancerogenesis and tumour progres-
sion is the elimination of cell intrinsic control and security
mechanisms such as cell cycle check points or apoptosis.
Therefore, tumour cells frequently escape programmed
cell death and show elevated proliferation rates. We have
previously shown that HDAC1-deﬁcient ES cells display re-
duced proliferation rates (Lagger et al, 2002). Therefore, we
next analysed proliferation and apoptosis rates in teratomas
derived from different genotypes in order to identify a possi-
ble aberration from the ES cell phenotype in our teratomas
model. For this purpose, we performed IHC stainings with
antibodies against the proliferation marker Ki67 and the
apoptosis marker cleaved Caspase 3 (Figure 1D). Upon
statistical evaluation, we unexpectedly found that prolifera-
tion was induced up to three-fold in HDAC1 /  teratomas
when compared with HDAC1 wild-type tumours. On the
other hand, apoptosis as detected with cleaved Caspase 3
IHC and TUNEL staining was also signiﬁcantly increased up
to ﬁve-fold in HDAC1 /  teratomas (Figures 1D and E).
TUNEL-positive areas in both wild-type and knockout
teratomas showed high expression of p53. High proliferation
and apoptosis was particularly obvious in epithelial areas in a
focal accentuated pattern. These areas consisted mainly of
undifferentiated cells. From these data, we conclude that
upon loss of HDAC1, proliferation as well as apoptosis are
elevated in teratomas, which explains that no signiﬁcant
differences in tumour size and weight were observed.
HDAC1 /  teratomas are undifferentiated and
reveal elevated Oct3/4 expression
HDAC inhibitors have been shown to delay tumour growth by
inducing cell cycle arrest, apoptosis, and cell differentiation
in cancer cells (Bolden et al, 2006; Glozak and Seto, 2007).
In order to investigate whether loss of HDAC1 in the experi-
mental teratoma model also exhibits similar effects proposed
by HDAC inhibitor treatment, we surveyed changes in cell-
type composition and differentiation state of HDAC1þ/þ
and HDAC1 /  teratomas via histological and IHC methods.
Haematoxylin and eosin (H&E) staining of these sections
revealed areas of all three germ layers including ectodermal
(neural tissue, neural glia, and dermal epithelium), mesoder-
mal (cartilage, bone, smooth, and striated muscle), and
deﬁnitive endodermal derivatives (digestive and respiratory
epithelium) in tumours derived from HDAC1 /  ES cells and
HDAC1þ/þ teratomas (Figure 2A). Furthermore, we also
identiﬁed parietal endoderm, an extraembryonic tissue deri-
vative (data not shown).
By detailed analysis, we identiﬁed a clear bias towards
undifferentiated epithelial cells (Figure 2A) in HDAC1 / 
teratoma sections. Based on cell composition and differentia-
tion grade, tumours from HDAC1 /  and HDAC1 / ev ES
cells were classiﬁed as embryonal carcinomas. Importantly,
HDAC1 /  ES cells with reintroduced HDAC1 (HDAC1 / re)
did not show these patterns indicating that the absence of
HDAC1 is directly linked with the carcinoma phenotype
(Figure 2A; data not shown). In order to conﬁrm a lower
state of teratoma differentiation upon loss of HDAC1, we next
asked whether the HDAC1 state inﬂuenced expression of
Oct3/4, an early stem cell marker. Western blot analyses
conﬁrmed expression of Oct3/4 in HDAC1 mutant teratomas,
whereas no Oct3/4 protein could be detected in HDAC1
wild-type teratomas (Figure 2B). In addition, ﬂuorescence
Figure 1 HDAC1 /  teratomas reveal elevated proliferation and increased apoptosis. In all, 3 10
6 mouse wild-type and HDAC1-deﬁcient ES cells
were subcutaneously injected in SCID/Balb/c mice and teratoma formation as well as tumour size was monitored every 4 days. Recipient SCID
mice were killed after 28 days post-injection and teratomas of both genotypes were removed and analysed. (A) Statistical comparison of the tumour
volume of HDAC1þ/þ (black bars) and HDAC1 /  (white bars) teratomas. The tumour volume (mm
3) was calculated using
the formula ‘(width
2 length)  1
2’. (B) Western blot analysis of protein extracts from ES cells used for the injection and three individual
HDAC1þ/þ (lanes 1–3) and HDAC1 /  teratomas (lanes 4–6). The membrane was probed with antibodies against HDAC1, HDAC2, and Actin
was used as loading control. (C–E) IHC analysis of representative HDAC1þ/þ and HDAC1 /  teratoma parafﬁn sections. The nuclei were
counterstained with Mayer’s hemalaun (blue staining). For quantiﬁcation, positively stained cells were evaluated by the HistoQuest Software as
shown in the graphs on the right. (C) IHC with antibodies against HDAC1 and HDAC2 (red AEC staining). All pictures were taken in a  20
magniﬁcation. (D) IHC with the proliferation marker Ki67 antigen (red AEC stain, upper panels) and the apoptosis marker Caspase 3 (red AEC
stain, lower panels). All pictures were taken in a  40 magniﬁcation. (E)H D A C 1þ/þ and HDAC1 /  teratoma sections were analysed using the
TUNEL apoptosis assay (ﬂuorescent green staining) and by IHC with p53 antibodies. All pictures were taken in a  20 magniﬁcation. *Po0.05;
**Po0.01; ***Po0.001.
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Oct3/4 in undifferentiated and/or dedifferentiated regions of
HDAC1 /  and HDAC1 / ev teratomas, whereas Oct3/4
expression was highly reduced in HDAC1-positive tumours
(Figure 2C). In order to rule out the possibility that higher
Oct3/4 levels in HDAC1 /  teratomas were a direct conse-
quence of already elevated Oct3/4 expression in HDAC1 / 
ES cells, we performed real-time PCR, northern and western
blot analyses (Figure 2B; data not shown). These experiments
showed no elevated Oct3/4 expression in HDAC1-deﬁcient ES
cells, suggesting that higher Oct3/4 expression is linked
to less efﬁcient differentiation of HDAC1 /  teratomas.
In summary, these data show that loss of HDAC1 leads to
generation of poorly differentiated teratocarcinomas.
Loss of HDAC1 leads to formation of embryonal
carcinomas
One important step during cancer formation and progression
is loss of the epithelial cell identity and break down of
intercellular junctions, which leads to the generation of
motile mesenchymal cells. As a consequence, tissue invasion
and ﬁnally metastasis occur. The process responsible for this
cell identity conversion is termed epithelial-to-mesenchymal
transition (EMT), and represents a key mechanism towards a
tumourigenic phenotype (Guarino, 2007). As EMT is accom-
panied by down-regulation of epithelial markers and up-
regulation of mesenchymal genes, the readout of gene
expression can be used to categorise aggressiveness and
staging of tumours. Therefore, we aimed to classify teratomas
generated from HDAC1þ/þ and HDAC1 /  ES cells ac-
cording to marker gene expression. First, we performed IHC
assays of teratoma sections with antibodies against the
epithelial markers E-cadherin and Cytokeratin to identify
the amount of differentiated epithelium in tumour samples
(Figure 3A; Supplementary Figure S2). In tumours of both
genotypes, E-cadherin and Cytokeratin-positive areas were
identiﬁed, although the expression level and pattern varied
signiﬁcantly. In both HDAC1þ/þ and HDAC1 /  teratomas,
highly differentiated epithelium, revealing luminal structures
expressing typical membrane-bound E-cadherin was detected
(Figure 3A, red arrows; Figure 3B). In addition to E-cadherin-
positive luminal structures, large patches with delocalised,
cytosolic E-cadherin, which resembled undifferentiated
epithelium (Figure 3A, blue arrows) were detected preferen-
tially in HDAC1-deﬁcient teratomas. The size of these patches
varied, but their abundance was signiﬁcantly increased in the
absence of HDAC1 (Figure 3A, right panel). Interestingly, the
areas of the tumour with cytosolic E-cadherin patterns were
associated with high proliferation (Ki67) and presence of p53
and Oct3/4 (Figure 3B; data not shown).
It has been shown that the interplay of several signalling
pathways is instrumental in accomplishing EMT. All cascades
ﬁnally converge in the activation of members of the SNAIL,
ZEB, and basic helix-loop-helix protein family (Guarino,
2007). These proteins are repressors, interacting with
HDAC1/2 and HDAC3 containing complexes thereby leading
to repression of the E-cadherin gene (Peinado et al, 2004).
Therefore, high expression of SNAIL1, the main inducer
of EMT is a crucial marker for tumourigenesis frequently
associated with poor prognosis in, for example, gastric
carcinomas, metastatic ovarian, and breast and prostate
carcinomas (Elloul et al, 2005; Castro Alves et al,2 0 0 7 ;
Peinado et al, 2007). In order to survey SNAIL1 expression
in the experimental teratoma model, we performed IHC
experiments with wild-type and HDAC1-deﬁcient tumours.
As shown in Figure 3C, we observed a signiﬁcant increase in
SNAIL1-positive cells upon loss of HDAC1.
Interestingly, areas in HDAC1 /  tumours with cytosolic
E-cadherin localisation showed also high SNAIL1 expression,
whereas SNAIL1 was absent in both wild-type and HDAC1 / 
tumours at luminal structures with E-cadherin staining at
adherens junctions (Figure 3D; data not shown). In agree-
ment with the increased expression of E-cadherin and
SNAIL1 in HDAC1-deﬁcient teratomas, we also observed
increased mRNA levels for both factors in the absence of
HDAC1 (Figure 3E). Taken together, we ﬁnd in HDAC1-
deﬁcient teratomas large areas of highly proliferating cells
that show simultaneous presence of SNAIL1 and cytosolic
E-cadherin.
HDAC1 is a crucial regulator of SNAIL1 and E-cadherin
expression
Expression of the inducer of EMT, SNAIL1 is regulated by a
negative autoregulatory feedback mechanism. SNAIL1 binds
to an E-box present in the Snail1 promoter, thereby restricting
its expression and disruption of the feedback loop increases
intracellular levels of SNAIL1 (Peiro et al, 2006). On the other
hand, E-cadherin expression was shown to be negatively
regulated by SNAIL1 associated HDAC1/HDAC2 repressor
complexes (Peinado et al, 2004; von Burstin et al, 2009). In
order to test the possibility that HDAC1 contributes to the
repression of SNAIL1 and E-cadherin expression, we per-
formed further experiments in the embryonal carcinoma cell
line F9. The F9 cell line was established as a subline of a
mouse teratocarcinoma (reviewed in Alonso et al, 1991) and
is, therefore, an excellent system to study the role of HDAC1
in teratomas. First, we asked whether the genes for SNAIL1
and E-cadherin are regulated by HDAC activity in F9 cells. To
this end, we treated F9 cells for 6h with three different HDAC
inhibitors (trichostatin A (TSA), valproic acid (VPA), and
MS275) and analysed mRNA levels by qRT–PCR. As a con-
trol, we used retinoic acid (RA), a known inducer of Snail1
expression. As expected, short-term treatment with all HDAC
inhibitors tested signiﬁcantly increased both Snail1 and
E-cadherin expression (Figures 4A and B).
Next, we asked whether HDAC1 or HDAC2 are crucial for
the regulation of SNAIL1 in F9 cells. To this end, we ex-
pressed different shRNAs targeting either HDAC1 or HDAC2
and non-target control shRNAs by lentiviral infection of F9
cells (Figure 4C). Similar to ES cells and teratoma cells,
HDAC1-deﬁcient F9 cells express increased levels of HDAC2
and vice versa. Most of the HDAC1- and HDAC2-deﬁcient
F9 cells showed a signiﬁcant reduction in total enzymatic
activity in whole-cell extracts (Figure 4C). The cell lines
HDAC1-3 and HDAC2-1 showing the most efﬁcient knock-
down of HDAC1 and HDAC2, respectively (Figure 4C), were
used for further analyses. SNAIL1 is not only a transcriptional
repressor, but also an activator of transcription (reviewed in
Peinado et al, 2007). Silencing of HDAC1 in F9 cells resulted
in enhanced expression of Snail1 and of the negatively
regulated SNAIL1 targets E-cadherin and Col2a1, but also of
the positively regulated downstream target MMP9
(Figure 4D). In contrast, loss of HDAC2 had no effect on
expression of Snail1. However, HDAC2 silencing induced the
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PCNA, another known SNAIL1 target was not affected by
loss of either HDAC1 or HDAC2. Thus, HDAC1 is a crucial
regulator of SNAIL1 in embryonal carcinoma cells. In addi-
tion, HDAC1 and HDAC2 seem to contribute to the negative
regulation of SNAIL1 target genes in these cells.
To examine a putative direct recruitment of HDAC1 to
the Snail1 promoter, quantitative ChIP assays with HDAC1-
speciﬁc antibodies were performed in control shRNA and
HDAC1 knockdown F9 cells. HDAC1 was present at the E-box
regions within the promoters of the Snail1 gene and the
E-cadherin encoding Cdh1 gene in F9 cells (Cano et al,
2000; Peiro et al, 2006) (Figures 4E and F). Up-regulation of
Snail1 and E-cadherin expression in the absence of HDAC1
was accompanied by a slight increase in histone H3 acetyla-
tion, but not of histone H4 acetylation. Acetylation of H3K9 is
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(Wang et al, 2008) and recently, the H3K56ac mark
was shown to be a target for HDAC1 (Dovey et al, 2010).
Therefore, we analysed the presence of these marks at the
Snail1 and Cdh1 promoters. As shown in Figures 4E and F,
local acetylation at H3K9 and H3K56 was enhanced upon
silencing of HDAC1. Similarly, treatment with the HDAC
inhibitor TSA resulted in hyperacetylation of histone H3 at
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shown). In summary, the expression of SNAIL1 and its
positively regulated target MMP9 is induced upon HDAC1
knockdown. At the same time, negatively regulated SNAIL1
targets such as E-cadherin or Col2a1 are derepressed in the
absence of HDAC1. Furthermore, our data suggest that
HDAC1 is directly involved in regulating the expression of
Snail1 and E-cadherin in embryonal carcinoma cells.
SNAIL1 is an important mediator of the phenotype
of HDAC1 /  teratomas
Given the aforementioned role of SNAIL1 in tumourigenesis,
we next examined whether SNAIL1 contributes to the pheno-
type of HDAC1-deﬁcient teratomas. We infected HDAC1þ/þ
and HDAC1 /  ES cells with two lentiviral vectors contain-
ing two different shRNAs targeting Snail1 and corresponding
non-target controls. In contrast to teratomas and embryonal
carcinoma cells, SNAIL1 expression is not enhanced in
HDAC1 /  mouse ES cells (Figure 5A). Expression of
SNAIL1 shRNAs resulted in signiﬁcant reduction in SNAIL1
protein levels, whereas mismatch and non-target control
shRNAs had no effect. Two different SNAIL1 knockdown
cell lines and corresponding control cells were sub-
cutaneously injected in SCID/BALBc female mice to
create teratomas. Control teratomas (HDAC1þ/þ NT and
HDAC1 /  NT) were comparable with the HDAC1þ/þ and
HDAC /  tumours described above. As previously observed
for epidermal carcinomas (Olmeda et al, 2007), silencing of
SNAIL1 had a strong effect on teratoma formation. SNAIL1
knockdown resulted in a 61% reduction for HDAC1þ/þ and
81% reduction for HDAC1 /  teratomas in tumour volume
compared with the control teratomas (NT) 20 days after
injection (Figure 5B). Quantiﬁcation of SNAIL1-positive
cells and their signal intensity revealed a strong reduction
in SNAIL1 expression upon SNAIL1 knockdown in both
HDAC1þ/þ and HDAC1 /  teratomas (Figure 5C).
Importantly, knockdown of SNAIL1 resulted in loss of the
hallmarks of HDAC1-deﬁcient teratomas, namely delocalised
cytosolic E-cadherin and increased cell proliferation. As
shown in Figures 5D and E, SNAIL1 knockdown in
HDAC1 /  teratomas signiﬁcantly reduced the presence of
patches with cytosolic E-cadherin staining and the number of
highly proliferating Ki67-positive cells. These results suggest
that SNAIL1 strongly contributes to the phenotype of
HDAC1 /  teratomas.
Human patient teratoma samples mirror the murine
phenotype
In humans, ovarian and testicular teratomas are relatively
common in young individuals. However, although ovarian
teratomas are generally benign, testicular teratomas are
malignant and often contain undifferentiated embryonal
carcinoma cells, which are highly malignant and are, there-
fore, known as teratocarcinomas (reviewed in Andrews,
2002). In the ﬁnal experiments, we were interested whether
results obtained from the experimental mouse teratoma
model had relevance in human disease. Therefore, we ana-
lysed 16 human germ cell tumours. Samples were classiﬁed
according to the World Health Organization guidelines. The
different tissue compartments were categorised according to
the stage of differentiation in mature (well-differentiated
tissue like in adults) and immature teratomas (tissue in any
stage of fetal development) and obviously malignant tissues
such as embryonal carcinomas and yolk sac tumours
(Figure 6A). With this categorisation, we addressed the question
whether the differentiation state of human teratomas was
correlated to expression of HDAC1. Remarkably, all markers
tested earlier in the mouse system showed similar expression
patterns in human teratomas. For instance, SNAIL1 expression
was frequently detected in all human teratomas tested; how-
ever, an increase by 46% in SNAIL1 expression appeared in
undifferentiated human tumours (Figure 6B). Furthermore, the
marker for undifferentiated ES cells Oct3/4 revealed high
expression levels in undifferentiated tumours when compared
with mature teratomas (Figure 6C).
Consequently, we asked whether HDAC1 expression in
human teratomas was also linked to a more differentiated,
mature phenotype. To this end, we used consecutive tissue
sections of mature and immature human teratomas
and stained with antibodies against HDAC1 and HDAC2.
Strikingly, we identiﬁed a largely divergent expression pattern
of HDAC1 and HDAC2 in human tumours of distinctive
differentiation grades. HDAC1 was preferentially detected in
mature areas of differentiated tumours, whereas HDAC2 was
absent in the same regions (Figure 6D). Conversely, in un-
differentiated aggressive teratocarcinomas, HDAC1 staining
was largely underrepresented, whereas HDAC2 was highly
expressed (Figure 6E). In eight mature teratomas from
human patients, we found that HDAC1 was highly expressed
in differentiated tumour areas, but weakly detected in tumour
stroma and mesenchymal cells (Table I). In contrast, HDAC2
was found to be lowly expressed in differentiated areas of
teratomas, but highly expressed in undifferentiated regions
and tumour stroma. In nine malignant tumours of the testis
(four immature teratomas, two embryonal carcinomas, two
seminomas, and one yolk sack tumour), the HDAC1 expres-
sion levels were in general much lower than the HDAC2
expression levels. In summary, our data show that samples
from patients with aggressive undifferentiated teratomas show
low levels of HDAC1 expression and are highly comparable
with HDAC1 /  mouse teratomas. Thus, we conclude that
human mature tumours were comparable with mouse
HDAC1þ/þ teratomas, whereas human immature tumours
revealed similarity to mouse HDAC1 /  teratomas.
Figure 3 Loss of HDAC1 leads to formation of embryonal carcinomas. IHC analysis of parafﬁn-embedded HDAC1þ/þ and HDAC1 /  mouse
tissue sections. Blue staining represents the counterstain performed with Mayer’s hemalaun solution. (A) Overview picture ( 2.5 magniﬁcation) of
typical HDAC1þ/þ and HDAC1 /  sections stained with E-cadherin-speciﬁc antibody. Luminal E-cadherin-stained structures are marked with red
arrows, patches with cytosolic E-cadherin with blue arrows. The presence of cytosolic E-cadherin patches was quantiﬁed using the HistoQuest
Software as shown in the graph on the right. (B) E-cadherin localisation in luminal structures of an HDAC1þ/þ tumour and patches preferentially
observed in HDAC1 /  tumours. Consecutive sections of the HDAC1 /  tumour were stained in addition with antibodies speciﬁc for Ki67 and p53
( 40 magniﬁcation, framed regions are shown as zoomed pictures). (C) SNAIL1 was detected in HDAC1þ/þ and HDAC1 /  teratomas by IHC
( 20 magniﬁcation). Quantiﬁcation of SNAIL1-positive cells is shown in the graph on the right. (D) IHC analysis of luminal structures or cytosolic
patches with E-cadherin and SNAIL1 antibodies ( 20 magniﬁcation). (E) qRT–PCR analysis of mRNA from HDAC1þ/þ and HDAC1 / 
teratomas for E-cadherin and Snail1 using Gapdh for normalisation. *Po0.05; **Po0.01; ***Po0.001.
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In this study, we have analysed the function of HDAC1 for
tumour development by using an experimental mouse tera-
toma model. We show that loss of HDAC1 has an unexpected
effect on proliferation and differentiation of murine terato-
mas. Analysis of teratomas generated from HDAC1 /  ES
cells revealed increased levels of proliferation and apoptosis
and showed that HDAC1-deﬁcient teratomas resembled
aggressive embryonal carcinomas. These effects were
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with DMSO or with retinoic acid (RA) as control or the HDAC inhibitors MS275, valproic acid (VPA), and trichostatin A (TSA). Expression of
Snail1 and E-cadherin was normalised to the housekeeping gene Hprt and shown relative to the DMSO treatment (set to 1). (C) shRNA-
mediated silencing of HDAC1 and HDAC2 in F9 cells. Western blot analyses of HDAC1 and HDAC2 protein upon stable expression of a non-
targeting control shRNA (NT) or three different shRNAs either targeting HDAC1 or HDAC2 (left panels). The membranes were probed with
antibodies against HDAC1, HDAC2, and Actin as loading control. An unspeciﬁc band on the HDAC1 blot is marked with an asterisk. Cellular
HDAC activity was measured in duplicates in two independent experiments (right panels). (D) Expression of SNAIL1 and SNAIL1 target genes
in control cells (NT), the HDAC1 shRNA cell line 1–3, and the HDAC2 shRNA cell line 2–1 was analysed by qRT–PCR. mRNA expression was
normalised to Hprt and shown relative to the untreated sample (set to 1). (E, F) Quantitative ChIP analysis of the presence of HDAC1 and
changes in histone acetylation patterns at the Snail1 (E) and Cdh1 (F) promoters. Chromatin was precipitated with an unspeciﬁc antibody (IgG)
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C-terminus. qRT–PCR was performed with primers speciﬁc for E-box containing part of the Snail1 and Chd1 promoters. Values for each ChIP
were normalised to the input and changes in histone acetylation are shown relative to the H3 C-terminus signal to correct for changes in
nucleosomal density. *Po0.05; **Po0.01; ***Po0.001.
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Figure 5 SNAIL1 as crucial mediator of the phenotype of HDAC1 /  teratomas. (A) shRNA-mediated silencing of SNAIL1 in HDAC1þ/þ
and HDAC1 /  ES cells. Expression of SNAIL1 protein upon stable expression of a non-targeting control shRNA (NT) or two different SNAIL1
shRNAs (SN1-1 and SN1-2) in HDAC1þ/þ and HDAC1 /  ES cells was analysed on western blots. The membranes were probed with
antibodies against SNAIL1 and Actin as loading control. (B–E) ES cells shown in (A) were subcutaneously injected in SCID/Balb/c mice and
teratoma formation as well as tumour size was monitored every 4 days. Recipient SCID mice were killed after 20 days post-injection, and
teratomas were removed and analysed. (B) Statistical comparison of the tumour volume of NTcontrols (black bars) and SNAIL1 knockdown
(SN1) teratomas (white bars). The tumour volume (mm
3) was calculated using the formula ‘(width
2 length)  1
2’. (C) Quantiﬁcation of
IHC analysis of representative HDAC1þ/þ and HDAC1 /  control (NT) and SNAIL1 (SN1) knockdown teratoma parafﬁn sections with
SNAIL1 antibody. The intensities of SNAIL1 positively stained cells were evaluated by the HistoQuest Software and are shown separately for
HDAC1þ/þ and HDAC1 /  tumours. (D, E) IHC analysis of representative HDAC1 /  control (HDAC1 / NT) and SNAIL1 knockdown
teratoma (HDAC1 / SN1) parafﬁn sections with antibodies speciﬁc for E-cadherin (D) and Ki67 (E). The nuclei were counterstained
with Mayer’s hemalaun (blue staining). All pictures were taken in a  20 magniﬁcation. (D) Patches with cytosolic E-cadherin staining were
evaluated by the HistoQuest Software as shown in the graphs on the right. (E) Quantiﬁcation of Ki67-positive cells is shown in the graph on
the right. *Po0.05; **Po0.01; ***Po0.001.
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ES cells. Hyperproliferation in the teratoma model was in
contrast to earlier ﬁndings, in which loss of HDAC1 led to
reduced proliferation rates accompanied by increased
levels of the CDK inhibitors p21 in ES cells or ﬁbroblasts
(Lagger et al, 2002; Zupkovitz et al, 2010). Similarly, primary
A
H
&
E
Mature teratomas Immature teratomas
B
20
10
0
40
50
60
70
80
90
100
30
Immature teratomas Mature teratomas
S
N
A
I
L
1
n = 4 ***
Immature Mature
%
 
S
N
A
I
L
1
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
Immature teratomas Mature teratomas
O
C
T
3
/
4
20
10
0
40
50
60
70
80
90
100
30
%
 
O
C
T
3
/
4
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
n = 4 ***
Mature Immature
C
HDAC2 HDAC1
M
a
t
u
r
e
 
t
e
r
a
t
o
m
a
s
%
 
H
D
A
C
1
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
20
10
0
40
50
60
70
80
90
100
30
Mature Immature
n = 4 ***
D
HDAC1
I
m
m
a
t
u
r
e
 
t
e
r
a
t
o
m
a
s
HDAC2 HDAC1 E
Mature
20
10
40
50
60
70
80
90
100
30
0
n = 4 ***
HDAC2
Immature
%
 
H
D
A
C
2
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
Figure 6 Human patient teratomas reﬂect the murine phenotype. (A) Two mature teratoma and two immature teratoma tissue sections were
stained with H&E and antibodies against SNAIL1 (B) and OCT3/4 (C). Pictures were taken in a  20 magniﬁcation or  10 magniﬁcation.
(D–E) Tissue sections from two mature teratomas and two immature teratomas were stained with antibodies against HDAC1 and antibodies
against HDAC2. Pictures were taken in a  20 magniﬁcation. ***Po0.001.
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absence of HDAC1 and HDAC2 (Haberland et al, 2009a;
Wilting et al, 2010; Yamaguchi et al, 2010) and loss of
HDAC1 in human tumour cells was linked with reduced
proliferation and increased apoptosis (Senese et al, 2007).
The proliferation effect observed in HDAC1/HDAC2-deﬁcient
ﬁbroblasts was linked to increased levels of the CDK inhibi-
tors p21 and p57. In contrast, conditional deletion of HDAC1
in peripheral Tcells led to increased cytokine expression and
enhanced proliferation (Grausenburger et al, 2010). These
ﬁndings suggest that the effect of HDAC1 on proliferation
depends on cell type-speciﬁc targets.
Interestingly, elevated proliferation in HDAC1-deﬁcient
teratomas was particularly pronounced in poorly differen-
tiated epithelial tumour areas, which are characterised by the
simultaneous presence of cytosolic E-cadherin and its repres-
sor SNAIL1. A co-localisation of SNAIL1 with in this
case membrane-bound E-cadherin was also observed in
Suz12-deﬁcient embryos, which lack a functional Polycomb
complex 2 (Herranz et al, 2008), indicating that different
histone-modifying enzymes are involved in the control of
SNAIL target genes. Silencing of HDAC1 in embryonal carci-
noma cells revealed that SNAIL1, E-cadherin, and other
SNAIL1 target genes are up-regulated in the absence of
HDAC1. SNAIL1 is not only a repressor of differentiation-
speciﬁc genes such as E-cadherin and Col2a1, but also
activates metastatic genes such as MMP9 and ZEB1
(Peinado et al, 2007). Importantly, loss of HDAC1 results in
the activation of both types of SNAIL1 targets. For instance,
expression of ZEB1 a downstream target of SNAIL1 is also
up-regulated in HDAC1 null teratomas (SL and CS, unpub-
lished data). In this scenario, SNAIL1 and its pro-proliferative
targets seem to have a dominant function given the partially
impaired epithelial differentiation in HDAC1-deﬁcient terato-
mas. The cytosolic localisation of E-cadherin might be due to
the SNAIL1-dependent activation of tumourigenicity promot-
ing factors that interfere with the formation of cell junctions
and epithelial structures.
The HDAC1 knockdown experiments and ChIP assays in
embryonal carcinoma cells revealed a direct role of HDAC1
in the regulation of SNAIL1 and E-cadherin. These data are in
accordance with studies showing a crucial role for SNAIL1
together with HDAC1/HDAC2 in the repression of E-cadherin
in tumour cells (Peinado et al, 2004; von Burstin et al, 2009)
and a report on the autoregulation of SNAIL1. Furthermore,
expression of SNAIL1 was shown to be increased in response
to HDAC inhibitor treatment of ovarian carcinoma cells
(Hayashi et al, 2010). Thus, HDAC1 acts as a negative
regulator of both SNAIL1 and some SNAIL1 target genes
including E-cadherin.
In addition to increased proliferation, we also observed
enhanced apoptosis in HDAC1 /  teratomas in the absence
of HDAC1. SNAIL1 was also described as a survival factor
(reviewed in Peinado et al, 2007). However, the simultaneous
presence of conﬂicting proliferation and differentiation
signals might cause the enhanced apoptosis observed in
HDAC1 null tumours. Increased apoptosis was previously
observed upon loss of HDAC1 in human tumour cells and
was linked to a mitotic defect of HDAC1 ablated tumour cells
(Senese et al, 2007). Moreover, a recent study showed that
overexpression of HDAC1 in human melanoma cells granted
resistance to HDAC inhibitor induced p53-dependent apopto-
sis, whereas knockdown of HDAC1 sensitised cells for pro-
grammed cell death (Bandyopadhyay et al, 2004). In general,
tumour cells seem to respond to HDAC1 ablation by apopto-
sis, whereas untransformed HDAC1-deﬁcient cells tend to
arrest in the G1 phase of the cell cycle. In ﬁbroblasts,
HDAC2 can in part compensate for the loss of HDAC1 and
only deletion of both enzymes results in cell death
(Haberland et al, 2009a; Wilting et al, 2010; Yamaguchi
et al, 2010).
In agreement with a report on tumours derived from
epidermal carcinoma cell lines (Olmeda et al, 2007),
SNAIL1 shRNA teratomas showed signiﬁcantly reduced pro-
liferation. Strikingly, upon reduction of SNAIL1 levels,
HDAC1 /  teratomas showed a more differentiated appear-
ance with a signiﬁcant reduction of cytosolic E-cadherin
patches. These data support the idea that SNAIL1 is a crucial
mediator of increased proliferation and reduced epithelial
differentiation in HDAC1 /  teratomas. However, this does
not exclude that other HDAC1-regulated factors contribute
to the observed phenotype. For instance, we have identiﬁed
several microRNAs that are known to be involved in prolif-
eration control as putative HDAC1 targets (SL and CS,
unpublished data).
Remarkably, the murine phenotype of HDAC1-deﬁcient
teratomas was mirrored in human patient samples. Similar
to the mouse teratoma model, HDAC1 was highly expressed
in mature (differentiated) human teratoma samples, whereas
HDAC2 was found overexpressed in immature (undifferen-
tiated) samples. Testicular germ cell tumours in man
develop from malignant undifferentiated cells. The malignant
transformation is due to an unknown mechanism during the
Table I HDAC1 and HDAC2 immunoreactivity in different compart-
ments of mixed germ cell tumours of 12 patients, teratoma
mature (Tm), teratoma immature (Ti), embryonal carcinoma (Ec),
seminoma (Sem), and yolk sac tumour (Ys)
No. Diagnosis Age Sex a-HDAC1 a-HDAC2
Teratoma mature
1 Tm 3 days F ++ +/ 
2 Tm 32 years M + ++
3 Tm 21 years F ++ +/ 
4 Tm 30 years M ++ +/ 
5 Tm 46 years M ++ +
6 Tm 22 years M ++ –
7 Tm 27 years M + –
8 Tm 3 days F ++ –
Teratoma immature
1 Ti 3 days F   +
2 Ti 32 years M +/  ++
3 Ti 30 years M +/  ++
4 Ti 46 years M +/  ++
Embryonal carcinoma
1 Ec 32 years M   ++
2 Ec 48 years M   +
Seminoma
1 Sem 48 years M ++ +++
2 Sem 44 years M ++ +++
Yolk sac tumour
1 Ys 48 years M   +
In these tumours, HDAC1 and HDAC2 are inversely expressed,
whereby HDAC1 shows high protein expression levels in mature,
and HDAC2 in immature tumour components.
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lar tubules. At later time points in life, they develop into
tumours and show different kinds of differentiation, giving
rise to a variety of morphologically different germ cell tu-
mours. This theory is supported by several biological ﬁndings
and also by clonal analysis of primary tumours and metas-
tases (Jones et al, 2006). It is likely that epigenetic processes
including changes in histone modiﬁcations affect the devel-
opment of germ cell tumours. Our results suggest that HDAC1
and HDAC2 could represent valuable prognostic markers for
teratocarcinoma classiﬁcation in the future.
Ablation of several HDACs including HDAC1, HDAC2,
HDAC3, and HDAC6 has been shown to negatively affect
the proliferation of tumour cells making these enzymes to
potential targets for anti-tumour drugs (Glaser et al, 2003;
Senese et al, 2007; Lee et al, 2008; Haberland et al, 2009a).
We present here for the ﬁrst time data indicating that
HDAC1 is required to attenuate proliferation in tumours. Do
our results suggest that inhibition of HDAC1 by anti-tumour
drugs would have an undesired and disadvantageous growth-
stimulating effect? We would predict that simultaneous abla-
tion of HDAC1 and HDAC2 would interfere with tumour cell
proliferation. Given the observed loss of cell viability upon
simultaneous ablation of HDAC1 and HDAC2 in several
cell systems (Haberland et al, 2009a; Wilting et al,2 0 1 0 ;
Yamaguchi et al, 2010), one would predict that inhibitors that
target both HDAC1 and HDAC2 would interfere with tumour
cell proliferation.
Materials and methods
Animal care
All experiments were performed in accordance with the Austrian
guidelines for animal care and protection.
Human teratoma patient samples
Human teratoma samples were obtained from the archives of the
Department of Clinical Pathology of the Vienna General Hospital
(AKH).
Cell culture
The following mouse ES cell lines were used in this study: HDAC1
wild-type (HDAC1þ/þ) and HDAC1 homozygous mutant
(HDAC1 / ) ES cells (Lagger et al, 2002). HDAC1 /  ES cells
were stably transfected with the ES cell-speciﬁc expression vector
pMSCVpuro-HDAC1 (designated HDAC1 / re) or with the corre-
sponding empty expression vector as control (HDAC1 / ev)
(Zupkovitz et al, 2006). All experiments were performed with ES
cell lines obtained from littermates. ES cells were cultured as
previously described (Zupkovitz et al, 2006). The F9 mouse
embryonal carcinoma cell line was cultured in DMEM supplemen-
ted with 10% fetal calf serum and antibiotics (0.003% w/v
penicillin and 0.005% w/v streptomycin) under 7.5% CO2.
shRNA-mediated silencing
For gene silencing pLKO.1 lentiviral vectors (Moffat et al, 2006)
with shRNA expression cassettes targeting mouse Snail1, Hdac1,
and Hdac2 and corresponding controls were created and used for
infection of mouse ES cells and F9 cells as described in the
Supplementary data. Following transduction, cells were selected
with 2mg/ml puromycin.
Inhibitor treatments
Three biological replicas of F9 embryonal carcinoma cells were
treated for 6h with either 1mM RA in DMSO (RA), 2mM MS275 in
DMSO, 10mM VPA in PBS (VPA), 66.1nM TSA in DMSO or DMSO
only as a control.
Total RNA isolation and real-time PCR analysis
Cells were harvested with TRIZOL reagent (Invitrogen), and total
RNA was isolated following the manufacturer’s instructions. RNA
was reversely transcribed with the iScript cDNA synthesis kit (Bio-
Rad). Real-time PCR analysis was performed with the KAPA SYBR
FAST qPCR MasterMix (Peqlab) on iCycler IQ system (Bio-Rad).
Chromatin immunoprecipitation and PCR analysis
Preparation of soluble chromatin and chromatin immunoprecipita-
tion assays were carried out as previously described (Hauser et al,
2002). Equal amounts of chromatin were diluted 10-fold, pre-
cleared, and precipitated over night with the following antibodies:
HDAC1, HDAC2, acetyl histone H3, acetyl histone H4, and H3K9ac
from Millipore; HDAC1, H3K56ac, C-terminal H3 from Abcam, and
IgG as a control. The extracted DNA was then used for quantitative
PCR analysis using an iCycler IQ system (Bio-Rad). PCRs with 1:40
dilutions of genomic DNA (input) were carried out along with the
precipitated DNA. Primer sequences are listed in Supplementary
data.
Teratoma formation
Conﬂuent ES cells were trypsinised, washed with PBS, resuspended
in M15 medium, and injected subcutaneously (3 10
6 ES cells in a
total volume of 100ml) into the ﬂanks of 10-week-old SCID/Balb/c
female mice (Harlan Laboratories, Indianapolis, IN). Teratoma
formation was monitored every 4 days, and tumour size was
measured using a Vernier caliper. Tumour volume was estimated
using the formula ‘(width
2 length)  1
2’ (Gotzmann et al, 2002,
2004). Statistical analysis of teratomas was performed with
GraphPad Prism software, and standard error of mean is indicated.
Recipient SCID mice were killed 20, 24, or 28 days after injection,
and teratomas were removed, measured, weighed, photographed,
and either ﬁxed in 4% phosphate-buffered formaldehyde overnight
at 41C for histological analyses or frozen in liquid nitrogen for
protein isolation.
Histological and IHC analyses
Histological analyses were performed on formalin-ﬁxed and
parafﬁn-embedded tissue. H&E staining was performed on 4mm
thick sections according to the standard procedures. For ﬂuores-
cence staining, the Tyramide Signal Ampliﬁcation Kit (PerkinElmer)
was used, and the manufacturer’s instructions were followed.
The slides were mounted with DAPI in Vectashield (Vector
Laboratories). Primary antibodies for IHC: p53 (Novocastra), Ki67
Antigen (Novocastra); SNAIL1 (Abcam), HDAC1 and HDAC2
(Millipore), E-cadherin (BD Transduction Laboratories), Oct3/4
(Santa Cruz), and cleaved Caspase-3 (Cell Signaling). Primary
antibodies were detected by the Immunoperoxidase method using
the IDetect Super Stain System HRP (ID labs Biotechnology).
Signals were ampliﬁed using 3-amino-9-ethylcarbazole (ID labs
Biotechnology) under visual control. Afterwards, the sections were
counterstained with Mayer’s hemalaun.
Apoptosis assay
An in situ cell death detection kit (Roche) was used to detect
apoptotic cells in teratomas, and the manufacturer’s instructions
were followed. Slides were mounted in Vectashield (Vector
Laboratories) containing DAPI to counterstain DNA. Positive
(DNase I-treated slides) and negative controls were included in
each experiment.
Microscopy
IHC stainings were imaged on a Zeiss stereomicroscope with
camera. Fluorescent IHC stainings were analysed on a Zeiss LSM
Meta 510 confocal microscope.
Protein isolation, western blot analyses, and HDAC activity
assays
For protein isolation, ES cell pellets or frozen teratoma samples
were homogenised in Hunt buffer (20mM Tris–HCl pH 8.0, 100mM
NaCl, 1mM EDTA, 0,5% w/v NP-40) in the presence of protease
inhibitor cocktail (Complete, Roche) with a freeze-and-thaw
method. Equal amounts of proteins (20–40mg) were separated by
SDS–PAGE (10% gels) and transferred onto nitrocellulose mem-
branes (Protran, Whatman) according to the standard protocols.
The enhanced chemiluminescent kit (PerkinElmer) was used for
protein detection. Primary antibodies for western blotting: HDAC1
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and Actin (Sigma). HDAC activity assays were performed with
whole-cell extracts as previously described (Lagger et al, 2002).
Statistical analysis
IHC images were photographed with the HistoFAXS system using a
Zeiss microscope. Stainings were quantiﬁed with the HistoQUEST
software provided by TissueGnostics GmbH, Vienna, Austria. IHC
images were statistically evaluated using the unpaired two-tailed
Student’s t-test calculated with the GraphPad Prism software
and s.d. is indicated. All real-time PCR and chromatin immunopre-
cipitation experiments were evaluated with Microsoft Excel and
P-values were calculated with the paired Student’s t-test (Graph-
Pad Prism software) and s.d. is shown. *Po0.05; **Po0.01;
***Po0.001.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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